Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 142 | 0.540 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 5 | 2016 | 230 | 0.490 |
Why?
|
| Bone Neoplasms | 1 | 2019 | 256 | 0.480 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 7 | 2016 | 1182 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 1721 | 0.410 |
Why?
|
| Patient Selection | 2 | 2020 | 719 | 0.400 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 158 | 0.360 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2016 | 970 | 0.310 |
Why?
|
| Lung Neoplasms | 7 | 2016 | 2642 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 886 | 0.300 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 883 | 0.230 |
Why?
|
| Lactams, Macrocyclic | 2 | 2016 | 51 | 0.230 |
Why?
|
| Carbazoles | 2 | 2015 | 56 | 0.220 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 1358 | 0.210 |
Why?
|
| Piperidines | 2 | 2015 | 217 | 0.200 |
Why?
|
| Neoplasms | 1 | 2016 | 2884 | 0.170 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2020 | 541 | 0.170 |
Why?
|
| Pharmacogenomic Testing | 1 | 2020 | 62 | 0.150 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 173 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2020 | 248 | 0.140 |
Why?
|
| Pyrimidines | 3 | 2016 | 533 | 0.130 |
Why?
|
| Ipilimumab | 1 | 2017 | 40 | 0.130 |
Why?
|
| Brain Neoplasms | 2 | 2017 | 1322 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 8279 | 0.130 |
Why?
|
| Eligibility Determination | 1 | 2016 | 68 | 0.120 |
Why?
|
| Aged | 7 | 2020 | 25947 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 403 | 0.120 |
Why?
|
| Sex Distribution | 1 | 2016 | 386 | 0.120 |
Why?
|
| Scleroderma, Localized | 1 | 2015 | 11 | 0.110 |
Why?
|
| Pemetrexed | 1 | 2015 | 38 | 0.110 |
Why?
|
| Pyrazoles | 2 | 2016 | 510 | 0.110 |
Why?
|
| Informed Consent | 1 | 2016 | 198 | 0.110 |
Why?
|
| Acrylamides | 1 | 2015 | 70 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2013 | 7 | 0.100 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 94 | 0.100 |
Why?
|
| Spinal Neoplasms | 1 | 2013 | 37 | 0.100 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 2197 | 0.100 |
Why?
|
| Prognosis | 3 | 2016 | 4293 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2013 | 155 | 0.090 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 1465 | 0.090 |
Why?
|
| SEER Program | 1 | 2013 | 224 | 0.090 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 334 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2019 | 11695 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2015 | 629 | 0.090 |
Why?
|
| Pyridines | 1 | 2015 | 605 | 0.090 |
Why?
|
| Male | 10 | 2020 | 72406 | 0.090 |
Why?
|
| Middle Aged | 8 | 2017 | 35928 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 966 | 0.080 |
Why?
|
| Melanoma | 1 | 2017 | 761 | 0.080 |
Why?
|
| Mutation | 3 | 2016 | 4099 | 0.080 |
Why?
|
| Prevalence | 1 | 2016 | 2836 | 0.070 |
Why?
|
| Survival Rate | 1 | 2013 | 2092 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2019 | 5965 | 0.070 |
Why?
|
| Humans | 13 | 2020 | 144957 | 0.070 |
Why?
|
| Adult | 6 | 2017 | 40506 | 0.070 |
Why?
|
| United States | 2 | 2016 | 15988 | 0.060 |
Why?
|
| Female | 9 | 2020 | 78376 | 0.060 |
Why?
|
| Lactams | 2 | 2016 | 28 | 0.060 |
Why?
|
| Sulfones | 2 | 2016 | 127 | 0.060 |
Why?
|
| Aminopyridines | 2 | 2016 | 127 | 0.060 |
Why?
|
| Drug Substitution | 1 | 2020 | 63 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 365 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 3550 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 104 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 83 | 0.030 |
Why?
|
| Dermatitis | 1 | 2015 | 19 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 199 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 2029 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2015 | 501 | 0.030 |
Why?
|
| Radiosurgery | 1 | 2017 | 401 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 1098 | 0.020 |
Why?
|
| Binding Sites | 1 | 2015 | 1331 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2015 | 375 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 2032 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 783 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 2499 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1141 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 14126 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2017 | 17101 | 0.010 |
Why?
|
| Adolescent | 1 | 2017 | 22453 | 0.010 |
Why?
|